181 related articles for article (PubMed ID: 28738967)
1. [Recent Advances in Association of Estrogen and Non-small Cell Lung Cancer].
Ding X; Tang C; Wang Z; Liang J
Zhongguo Fei Ai Za Zhi; 2017 Jul; 20(7):499-504. PubMed ID: 28738967
[TBL] [Abstract][Full Text] [Related]
2. [Advances in Association of Estrogen and Human Non-small Cell Lung Cancer].
He J; Song X
Zhongguo Fei Ai Za Zhi; 2015 May; 18(5):315-20. PubMed ID: 25975303
[TBL] [Abstract][Full Text] [Related]
3. Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer.
Siegfried JM; Farooqui M; Rothenberger NJ; Dacic S; Stabile LP
Oncotarget; 2017 Apr; 8(15):24063-24076. PubMed ID: 28445992
[TBL] [Abstract][Full Text] [Related]
4. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells.
Pietras RJ; Márquez DC; Chen HW; Tsai E; Weinberg O; Fishbein M
Steroids; 2005; 70(5-7):372-81. PubMed ID: 15862820
[TBL] [Abstract][Full Text] [Related]
5. Targeting aromatase and estrogen signaling in human non-small cell lung cancer.
Márquez-Garbán DC; Chen HW; Goodglick L; Fishbein MC; Pietras RJ
Ann N Y Acad Sci; 2009 Feb; 1155():194-205. PubMed ID: 19250205
[TBL] [Abstract][Full Text] [Related]
6. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.
Stabile LP; Lyker JS; Gubish CT; Zhang W; Grandis JR; Siegfried JM
Cancer Res; 2005 Feb; 65(4):1459-70. PubMed ID: 15735034
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma.
Niikawa H; Suzuki T; Miki Y; Suzuki S; Nagasaki S; Akahira J; Honma S; Evans DB; Hayashi S; Kondo T; Sasano H
Clin Cancer Res; 2008 Jul; 14(14):4417-26. PubMed ID: 18579664
[TBL] [Abstract][Full Text] [Related]
8. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
9. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Gadgeel SM; Wozniak A
Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
[TBL] [Abstract][Full Text] [Related]
10. [Progress of c-MET Signaling Pathway and TKIs in Non-small Cell Lung Cancer].
Yu X; Xu Y; Fan Y
Zhongguo Fei Ai Za Zhi; 2017 Apr; 20(4):287-292. PubMed ID: 28442019
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor signaling pathways in human non-small cell lung cancer.
Márquez-Garbán DC; Chen HW; Fishbein MC; Goodglick L; Pietras RJ
Steroids; 2007 Feb; 72(2):135-43. PubMed ID: 17276470
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor signaling in non-small-cell lung cancer.
Semrad TJ; Mack PC
Clin Lung Cancer; 2012 Mar; 13(2):90-5. PubMed ID: 21959109
[TBL] [Abstract][Full Text] [Related]
13. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
[TBL] [Abstract][Full Text] [Related]
14. The P21-activated kinase expression pattern is different in non-small cell lung cancer and affects lung cancer cell sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
Liu Y; Wang S; Dong QZ; Jiang GY; Han Y; Wang L; Wang EH
Med Oncol; 2016 Mar; 33(3):22. PubMed ID: 26820570
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine.
Yin JY; Li X; Zhou HH; Liu ZQ
Pharmacogenomics; 2016 Aug; 17(12):1365-78. PubMed ID: 27462924
[TBL] [Abstract][Full Text] [Related]
16. Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women.
Schwartz AG; Wenzlaff AS; Prysak GM; Murphy V; Cote ML; Brooks SC; Skafar DF; Lonardo F
J Clin Oncol; 2007 Dec; 25(36):5785-92. PubMed ID: 18089876
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor expression and gene promoter methylation in non-small cell lung cancer - a short report.
Tekpli X; Skaug V; Bæra R; Phillips DH; Haugen A; Mollerup S
Cell Oncol (Dordr); 2016 Dec; 39(6):583-589. PubMed ID: 27572263
[TBL] [Abstract][Full Text] [Related]
18. Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
Nurwidya F; Takahashi F; Murakami A; Kobayashi I; Kato M; Shukuya T; Tajima K; Shimada N; Takahashi K
Respir Investig; 2014 Mar; 52(2):82-91. PubMed ID: 24636263
[TBL] [Abstract][Full Text] [Related]
19. Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer.
Tan F; Shi Y; Wang Y; Ding L; Yuan X; Sun Y
Future Oncol; 2015; 11(3):385-97. PubMed ID: 25675121
[TBL] [Abstract][Full Text] [Related]
20. Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
Chen Q; Quan Q; Ding L; Hong X; Zhou N; Liang Y; Wu H
Oncotarget; 2015 Sep; 6(28):24904-11. PubMed ID: 26172562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
